KURT W TAUER MD NPI 1053340802

NPI Details

Kurt W Tauer, MD is a medical oncology internal medicine in Germantown, TN with 45 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Kurt W Tauer, MD NPI is 1053340802. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1980

The provider's business location address is:

7945 WOLF RIVER BLVD
GERMANTOWN, TN
ZIP 38138-762
Phone: (901) 683-0055
Fax: (901) 922-6757

The NPI 1053340802 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Liver function blood test panel (HCPCS:80076)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99490)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Therapy procedure using manual technique, each 15 minutes (HCPCS:97140)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Ferritin (blood protein) level (HCPCS:82728)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Magnesium level (HCPCS:83735)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Blood creatinine level (HCPCS:82565)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Nephelometry, test method using light (HCPCS:83883)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes (HCPCS:97110)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Therapy procedure using functional activities (HCPCS:97530)
• Blood test, clotting time (HCPCS:85610)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Training for self-care or home management, each 15 minutes (HCPCS:97535)
• Automated urinalysis test (HCPCS:81003)
• Blood glucose (sugar) level (HCPCS:82947)
• Injection, mannitol, 25% in 50 ml (HCPCS:J2150)
• Flow cytometry technique for dna or cell analysis, 16 or more markers (HCPCS:88189)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) (HCPCS:G0506)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Ultrasound of heart with color-depicted blood flow, rate, direction and valve function (HCPCS:93306)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Vitamin d-3 level (HCPCS:82306)
• Injection, fentanyl citrate, 0.1 mg (HCPCS:J3010)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Injection of drug or substance into vein (HCPCS:96374)
• Folic acid level, serum (HCPCS:82746)
• Evaluation for physical therapy, typically 30 minutes (HCPCS:97162)

The enumeration date for this NPI number is 7/2/2006 and was last updated on 2/21/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.